HK1052868A1 - 药物组合物 - Google Patents

药物组合物 Download PDF

Info

Publication number
HK1052868A1
HK1052868A1 HK03104842.9A HK03104842A HK1052868A1 HK 1052868 A1 HK1052868 A1 HK 1052868A1 HK 03104842 A HK03104842 A HK 03104842A HK 1052868 A1 HK1052868 A1 HK 1052868A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical compositions
valsartan pharmaceutical
solid valsartan
solid
valsartan
Prior art date
Application number
HK03104842.9A
Other languages
English (en)
Chinese (zh)
Inventor
Maria Ganter Sabina
Frank Wagner Robert
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1052868A1 publication Critical patent/HK1052868A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK03104842.9A 2000-06-22 2001-06-20 药物组合物 HK1052868A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59968700A 2000-06-22 2000-06-22
US09/599,687 2000-06-22
PCT/EP2001/006983 WO2001097805A2 (en) 2000-06-22 2001-06-20 Solid valsartan pharmaceutical compositions

Publications (1)

Publication Number Publication Date
HK1052868A1 true HK1052868A1 (zh) 2003-10-03

Family

ID=24400655

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03104842.9A HK1052868A1 (zh) 2000-06-22 2001-06-20 药物组合物

Country Status (21)

Country Link
EP (2) EP1296677A2 (https=)
JP (3) JP2003535895A (https=)
KR (2) KR100525341B1 (https=)
CN (2) CN1221256C (https=)
AU (2) AU2001285768B2 (https=)
BR (1) BR0111868A (https=)
CA (1) CA2411882C (https=)
CZ (1) CZ20024180A3 (https=)
EC (1) ECSP024389A (https=)
HK (1) HK1052868A1 (https=)
HU (1) HUP0301390A3 (https=)
IL (2) IL153428A0 (https=)
MX (1) MXPA02012683A (https=)
NO (1) NO20026123L (https=)
NZ (2) NZ540748A (https=)
PL (1) PL358290A1 (https=)
RU (1) RU2333757C2 (https=)
SG (1) SG162605A1 (https=)
SK (1) SK18062002A3 (https=)
WO (1) WO2001097805A2 (https=)
ZA (1) ZA200210359B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE524176T1 (de) * 1998-12-23 2011-09-15 Novartis Pharma Gmbh Valsartan tablette
DK1467728T3 (da) * 2002-01-17 2007-12-27 Novartis Ag Farmaceutiske sammensætninger indeholdende valsartan og NEP-inhibitorer
US7468390B2 (en) 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
TWI299663B (en) * 2002-05-14 2008-08-11 Novartis Ag Methods of treatment
KR100882156B1 (ko) * 2003-08-08 2009-02-06 아지노모토 가부시키가이샤 나테글리니드 함유 제제
WO2006021443A2 (en) * 2004-08-26 2006-03-02 Novartis Ag Composition comprising an at1 receptor blocker and a macrolide t-cell immunomodulator
PT2033629E (pt) 2004-12-24 2013-01-24 Krka Composição farmacêutica sólida que compreende valsartan
JP2009001520A (ja) * 2007-06-21 2009-01-08 Kowa Co ジフェンヒドラミン含有固形製剤
EP2197416A1 (en) 2007-10-09 2010-06-23 Novartis Ag Pharmaceutical formulation of valsartan
WO2009059605A1 (en) * 2007-11-08 2009-05-14 University Of Copenhagen Small scale solid state screening
EP2067470A1 (en) * 2007-12-03 2009-06-10 Laboratorios Lesvi, S.L. Pharmaceutical compositions containing valsartan and process for its preparation
SI2536396T1 (sl) 2010-02-16 2017-01-31 KRKA, tovarna zdravil, d.d.,Novo mesto Postopek za pripravo oralnih trdnih odmernih oblik, ki obsegajo valsartan
CN102362865B (zh) * 2011-10-28 2013-06-26 山东司邦得制药有限公司 一种含有盐酸贝尼地平和缬沙坦的复方制剂及其应用
WO2013098576A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan
WO2013098578A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan hydrochlorothiazide
CN103599084B (zh) * 2013-11-22 2018-10-30 威海迪素制药有限公司 一种降压组合物
CN112826806A (zh) * 2021-01-20 2021-05-25 海南皇隆制药股份有限公司 一种缬沙坦片制备方法和缬沙坦片
CN112807286A (zh) * 2021-01-20 2021-05-18 海南皇隆制药股份有限公司 一种缬沙坦分散片制备方法和缬沙坦分散片
EP4295839A1 (en) 2022-06-20 2023-12-27 KRKA, d.d., Novo mesto Combination of valsartan and indapamide

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL97219A (en) 1990-02-19 1995-12-08 Ciba Geigy Ag Biphenyl substituted aliphatic amino compounds process for their preparation and pharmaceutical compositions containing them
HUT76542A (en) * 1994-03-17 1997-09-29 Ciba Geigy Ag Use of valsartan for the preparation of pharmaceutical composition serving for the treatment of diabetic nephropathy
DK0831910T3 (da) * 1995-06-07 2002-05-21 Searle & Co Kombinationsterapi med epoxy-steroid aldosteronantagonist og angiotensin II-receptorantagonist til behandling af kongestivt hjertesvigt
AU7213296A (en) * 1995-10-06 1997-04-30 Ciba-Geigy Ag At1-receptor antagonists for preventing and treating postischemic renal failure and for protecting ischemic kidneys
WO1997031634A1 (en) * 1996-02-29 1997-09-04 Novartis Ag At1 receptor antagonist for the stimulation of apoptosis
ATE255883T1 (de) * 1996-05-20 2003-12-15 Janssen Pharmaceutica Nv Fungizide mittel mit verbesserter bioverfügbarkeit
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US6541669B1 (en) * 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
ATE524176T1 (de) * 1998-12-23 2011-09-15 Novartis Pharma Gmbh Valsartan tablette
RU2298418C2 (ru) * 2000-04-12 2007-05-10 Новартис Аг Комбинация по меньшей мере двух соединений, выбранных из групп антагонистов at1-рецептора или ингибиторов асе (ангиотензинпревращающий фермент), или ингибиторов hmg-coa-редуктазы (бета-гидрокси-бета-метилглутарил-кофермент-а-редуктаза)

Also Published As

Publication number Publication date
EP1296677A2 (en) 2003-04-02
EP2072049A2 (en) 2009-06-24
KR100659644B1 (ko) 2006-12-21
RU2333757C2 (ru) 2008-09-20
AU2001285768B2 (en) 2005-03-10
PL358290A1 (en) 2004-08-09
WO2001097805A2 (en) 2001-12-27
NO20026123L (no) 2003-02-18
KR20030019450A (ko) 2003-03-06
ZA200210359B (en) 2003-11-13
MXPA02012683A (es) 2003-04-25
BR0111868A (pt) 2003-07-01
ECSP024389A (es) 2003-02-06
JP2003535895A (ja) 2003-12-02
IL153428A0 (en) 2003-07-06
SG162605A1 (en) 2010-07-29
CA2411882C (en) 2011-09-06
HUP0301390A2 (hu) 2003-11-28
KR20050085978A (ko) 2005-08-29
IL153428A (en) 2013-12-31
NO20026123D0 (no) 2002-12-19
CN1679551A (zh) 2005-10-12
CA2411882A1 (en) 2001-12-27
HUP0301390A3 (en) 2005-04-28
CZ20024180A3 (cs) 2003-04-16
NZ540748A (en) 2007-04-27
KR100525341B1 (ko) 2005-11-02
CN1437469A (zh) 2003-08-20
SK18062002A3 (sk) 2003-07-01
JP2012211200A (ja) 2012-11-01
WO2001097805A3 (en) 2002-08-29
CN100450478C (zh) 2009-01-14
NZ522953A (en) 2005-10-28
AU8576801A (en) 2002-01-02
EP2072049A3 (en) 2009-12-30
HK1083452A1 (zh) 2006-07-07
JP2007091758A (ja) 2007-04-12
CN1221256C (zh) 2005-10-05

Similar Documents

Publication Publication Date Title
HK1052868A1 (zh) 药物组合物
CA2427815A1 (en) Controlled release hydrocodone formulations
PL356358A1 (en) Solid dosage form of someticone for oral administration
WO2005032555A3 (en) Pharmaceutical combinations of hydrocodone and naltrexone
WO2001042219A3 (en) Novel substituted phenanthridinones and methods of use thereof
MXPA03006476A (es) Composiciones farmaceuticas, formas de dosificacion y metodos para administracion oral de epotilonas.
HRP20040545A2 (en) Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability
CA2339991A1 (en) Microemulsions as solid dosage forms for oral administration
TWI315204B (en) Oral dosage forms for propiverine or pharmaceutically acceptable salts thereof having prolonged release of the active agent
HUP0302319A3 (en) Pharmaceutical composition for oral administration of active ingredient
CA2382098A1 (en) Sustained-release, oral pharmaceutical forms of administration
IL150696A0 (en) Pharmaceutical compositions containing benzimidazole derivatives and processes for the manufacture thereof
IL212075A0 (en) Pharmaceutical compositions comprising a combination of a renin inhibitor and at least one therapeutic agent and uses thereof for the manufacture of medicaments for the prevention of, delay of progression of, or treatment of a disease
AU2003229555A1 (en) Oral administration form for difficulty soluble basic active ingredients which are applied orally
HUP0301921A3 (en) Sustained release pharmaceutical compositions for paranteral administration of hydrophilic compounds
CA2213700A1 (en) Pharmaceutical composition for piperidinoalkanol compounds
WO2002094774A3 (en) Oxcarbazepine dosage forms
GEP20063882B (en) Dosage regimen and pharmaceutical composition for emergency contraception
WO2007038112A3 (en) Combination of rosiglitazone and donepezil for improvement of cognitive function
PL348419A1 (en) Sustained-release pharmaceutical preparation containing tilidine mesylate as active ingredient
WO2006097943A3 (en) Pharmaceutical compositions of amlodipine and benazepril
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
CA2376847A1 (en) Complex of eletriptan and a cyclodextrin derivative
WO2005004836A3 (en) Saquinavir mesylate oral dosage form
WO2003070153A3 (en) Stabilized pharmaceutical compositions of halofuginone and other quinazolinone derivatives